A single-cell cohort study demonstrated that the patients with stage IV melanoma with a higher baseline ratio of circulating Ki67+PD-1+CD8+ T cells in peripheral blood relative to tumor burden would benefit from pembrolizumab treatment demonstrated [26]. The gene discussed is CD8A; the disease is melanoma.